However, the authors of a previous report suggested that BCAR3 expression is correlated with favorable outcome in progression-free survival (PFS) in a cohort of ER-positive (ER+) breast cancer patients who had received tamoxifen treatment [10]. This evidence concerns the gene BCAR3 and breast cancer.